Medicus Pharma (NASDAQ:MDCX) Releases Earnings Results, Misses Estimates By $0.13 EPS

Medicus Pharma (NASDAQ:MDCX) announced its quarterly earnings data on Thursday. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.13), Zacks reports.

Medicus Pharma Stock Up 5.3%

Shares of NASDAQ MDCX traded up $0.02 during mid-day trading on Thursday, reaching $0.34. 1,573,236 shares of the company were exchanged, compared to its average volume of 4,490,042. The company’s 50-day simple moving average is $0.45 and its 200-day simple moving average is $1.25. The stock has a market capitalization of $14.09 million, a P/E ratio of -0.12 and a beta of -0.47. Medicus Pharma has a twelve month low of $0.25 and a twelve month high of $8.94.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MDCX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a research report on Friday, April 10th. Roth Mkm started coverage on shares of Medicus Pharma in a research report on Tuesday, April 21st. They issued a “buy” rating for the company. Finally, D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Medicus Pharma in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $9.00.

Institutional Trading of Medicus Pharma

A number of hedge funds have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in Medicus Pharma in the 2nd quarter worth about $41,000. HRT Financial LP acquired a new stake in Medicus Pharma in the 4th quarter worth about $42,000. Osaic Holdings Inc. raised its stake in Medicus Pharma by 180.0% in the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after purchasing an additional 9,000 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in Medicus Pharma by 161.8% in the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after purchasing an additional 17,611 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Medicus Pharma in the 3rd quarter worth about $59,000.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.